Asia-Pacific Human Insulin Market Research Report: Forecast (2024-2030)

Market Definition

Insulin is a hormone produced by the pancreas that regulates blood sugar levels in the body. It mainly functions by aiding the transfer of sugar from the bloodstream to various body tissues, where it is utilized as energy. In medicine, human insulin is commonly manufactured using genetic engineering methods. This synthetic insulin is indistinguishable from the insulin naturally created by the human body. It is employed in diabetes treatment to substitute or complement the body's insulin production, aiding in the management of blood sugar levels & the prevention of diabetes-related complications.

Market Insights & Analysis: Asia-Pacific Human Insulin Market (2024-30):

The Asia-Pacific Human Insulin Market is estimated to grow at a CAGR of around 8.12% during the forecast period, i.e., 2024-30. The region is home to a large & rapidly growing population affected by diabetes. Urbanization, sedentary lifestyles, unhealthy dietary habits, and an aging population contribute to the increasing prevalence of diabetes in countries across the region. As diabetes rates soar, there is a growing need for accessible & affordable diabetes management solutions, including human insulin therapy.

Moreover, the demand for human insulin has improved over the years, which has been mainly attributed to the rising prevalence of gestational diabetes in pregnant women. Notably, this condition is more prevalent in low- & middle-income countries where access to maternal care is limited. Gestational diabetes mellitus (GDM) is the elevated blood sugar levels during pregnancy, typically resolving after childbirth. During pregnancy, the placenta generates hormones that disrupt the body's insulin utilization, a normal occurrence in gestation known as insulin resistance. Hence, as the instance of gestational diabetes has been amplifying across the region, the demand for human insulin has also increased.

Furthermore, increasing government initiatives and support for expanding & modernizing healthcare infrastructure are aimed at meeting the rising demand for diabetes care. This includes establishing specialized diabetes clinics, endocrinology departments, and diabetes centers equipped with advanced diagnostic and treatment facilities. Thus, the expansion of healthcare infrastructure is enhancing access to human insulin therapy for patients with diabetes, further driving market growth in the coming years.

Asia-Pacific Human Insulin Market Driver:

Surging Prevalence of Diabetes Boosting the Human Insulin Market – The Asia-Pacific Human Insulin Market has witnessed robust growth driven by a surge in diabetes prevalence over the historical years. This has been primarily attributed to factors such as changing lifestyles, increased obesity rates, and an aging population. Asia-Pacific aging demographics have also played a pivotal role as older individuals are more prone to diabetes. According to the Economic and Social Commission for Asia and the Pacific, the number of older persons is projected to more than double, from around 630 million in 2020 to about 1.3 billion by 2050. Hence, as the world experiences a demographic shift towards an older age structure, the prevalence of diabetes is on the rise. This demographic trend amplifies the demand for human insulin, which has aided in driving the Asia-Pacific Human Insulin Market.

Asia-Pacific Human Insulin Market Opportunity:

Rising Focus on Preventive Healthcare Among Consumers – The Asia-Pacific region is putting more emphasis on preventive healthcare and disease management, such as promoting healthy lifestyles and early detection and intervention for diabetes. This presents opportunities for companies to develop and market insulin products that are consistent with preventive care and disease management strategies.

In addition, early detection & screening programs for diabetes and its complications, such as retinopathy and nephropathy, are becoming increasingly prevalent in the Asia-Pacific region. These programs aim to detect diabetes at an early stage when interventions are most effective in preventing or delaying disease progression. Hence, insulin products that offer fast-acting formulations or convenient administration methods facilitate early detection & monitoring, enhancing patient outcomes & reducing the burden of diabetes-related complications, further anticipated to enhance the market size during 2024-30.

Asia-Pacific Human Insulin Market Challenge:

Inadequate Health Reimbursement & Lower Diagnosis Rate in Asia-Pacific to Impede the Market Growth – Inadequate health reimbursement results in patients being unable to afford insulin therapy, thereby reducing access to essential diabetes treatments. This issue is exacerbated by lower diagnosis rates, which limit the identification of individuals in need of insulin therapy. Consequently, a significant portion of the population across the Asia-Pacific region goes untreated or receives suboptimal care, thereby hindering market growth.

In addition, lower diagnosis rates across the region result in delayed initiation of insulin therapy, leading to inferior health outcomes, increased healthcare costs, and higher rates of morbidity & mortality. Thus, this delay negatively impacts the demand for insulin products, as patients require higher doses or more intensive treatment procedures, further creating a challenge for the Asia-Pacific Human Insulin Market expansion.

Asia-Pacific Human Insulin Market Trend:

Rapid Consumer Adoption of Human Insulin Biosimilars Posing Transformative Advancements in Diabetes Care – The growing adoption of human insulin biosimilars is driving transformative advancements in diabetes care, particularly in the Asia-Pacific region. Biosimilars typically offer cost-effective alternatives to branded insulin products. As more biosimilars enter the market, they contribute to increased accessibility & affordability of insulin therapy, especially in countries with large diabetic populations.

In addition, the availability of biosimilars increases the range of treatment options for individuals with diabetes in the Asia-Pacific region. Patients & healthcare providers have more choices, leading to personalized treatment plans that better suit individual needs and preferences, which is anticipated to enhance the market growth in the forthcoming years.

Asia-Pacific Human Insulin Market (2024-30): Segmentation Analysis

The Asia-Pacific Human Insulin Market study by MarkNtel Advisors evaluates & highlights the major trends and influencing factors in each segment & includes predictions for the period 2023–28 at the regional level. In accordance to the analysis, the market has been further classified as:

Based on End User:

• Hospital/Clinics
• Home/Personal

Hospitals & Clinics hold the potential share of the Asia-Pacific Human Insulin Market, as they serve as central hubs for the diagnosis, treatment, and management of diabetes. They provide broad care to patients with diabetes, including access to human insulin therapy, medical consultations, diagnostic tests, medication management, and diabetes education programs. They offer a wide range of diabetes services tailored to the needs of individual patients. These services include diabetes screening & diagnosis, glycemic control monitoring, insulin initiation & titration, diabetes self-management education, nutritional counseling, and foot care clinics for diabetic foot ulcers.

In addition, hospitals & clinics have access to advanced treatment modalities & technologies for diabetes management, including insulin pumps, continuous glucose monitoring (CGM) systems, and telemedicine platforms. These technologies enhance the delivery of diabetes care, improve treatment outcomes, and increase patient convenience & satisfaction, which positively enhance the market growth during 2024-30.

Based on Application:

• Type I Diabetes
• Type II Diabetes

Type II diabetes is one of the most common diabetes across the Asia-Pacific region, and according to the International Diabetes Federation, it accounts for almost 90% of the overall diabetes cases. The factors responsible for the higher prevalence of type 2 diabetes are lifestyle factors and genetic predisposition. Individuals with a family history of type 2 diabetes have been at a higher risk of developing the condition. As genetic factors play a crucial role in determining an individual's susceptibility to insulin resistance and impaired glucose metabolism, the instances of type 2 diabetes have been multiplying over time. Hence, type 2 diabetes has been one of the major applications of human insulin over the historical years & would be crucial in the years ahead as well.

Asia-Pacific Human Insulin Market (2024-30): Country Projection

Geographically, the Asia-Pacific Human Insulin Market expands across:

• China
• India
• Japan
• South Korea
• Southeast Asia
• Australia
• Rest of Asia-Pacific

The rising geriatric population and increased prevalence of diabetes in China have accelerated the domestic consumption of human insulin during the historical years. As consumers age, they are more susceptible to developing type 2 diabetes due to factors such as decreased physical activity, changes in metabolism, and other age-related health conditions. According to the World Health Organization (WHO), China has one of the fastest-growing aging populations in the world. By 2040, an estimated 402 million people (28% of the total population) will be over the age of 60 in 2040 due to longer life expectancy & declining fertility rates.

With China's aging population, there is a higher incidence of diabetes among the elderly, leading to an increased demand for insulin across the country, further making it the largest share-holding country among others in the APAC Human Insulin Market.

Asia-Pacific Human Insulin Market Recent Development:

• 2023: Novo Nordisk, launched once-a-week insulin regime for Indian patients. The company is conducting trials in around 27 sites involving 217 patients in India.
• 2023: Lilly Eli Lilly and Company, supplied its active pharmaceutical ingredient (API) for human insulin at a reduced price to International Agencies (Bangladesh) Ltd. (IABL) in an effort to increase patient access & improve affordability for high-quality insulin for nearly one million customers living with diabetes in Bangladesh by 2030.

Gain a Competitive Edge with Our Asia-Pacific Human Insulin Market Report

• Asia-Pacific Human Insulin Market Report by MarkNtel Advisors provides a detailed & thorough analysis of market size & share, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics & make informed decisions.
• This report also highlights current market trends & future projections, allowing businesses to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
• Asia-Pacific Human Insulin Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.